S. 935 · 118th Congress · Health
Fair Accountability and Innovative Research Drug Pricing Act of 2023
- IntroducedMar 22, 2023 Done
- CommitteeDied Jan 3, 2025 Stopped here
- Senate floorNot yet Not reached yet
- House floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill requires manufacturers to report about certain price increases for prescription drugs and biological products with a wholesale cost of at least $100 per month.
Such reports must include, among other information (1) the percentage price increase, (2) a justification for such increase, (3) the price history of the drug, (4) the total cost to develop the drug, and (5) the total revenue and net profit generated from the drug. Manufacturers are subject to civil penalties for failing to comply with the bill's requirements. Additionally, the Food and Drug Administration must post the information on its website.
Congressional Research Service · summary of “Introduced in Senate” version · Mar 22, 2023
Who lobbies on it
2 organizations · 12 filings · Q1 2023–Q4 2024One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
American Academy of Dermatology Association
7 of 8 quarters
“…S. 935, the Fair Accountability & Innovative Research (FAIR) Drug Pricing Act. Support H.R. 4968, Getting Over Lengthy Delays in Care as Required by Doctors (GOLD CARD) Act. Support H.R.2389/S.1302, the Resident Physicians Shortage Reduction Act. Advocate regarding matters related to Merit-based Incentive Payment…”
$2.8M lobbying spend in 2024, all issuesQ4 2024 filing
-
Pharmaceutical Research and Manufacturers of America
5 of 8 quarters
“…S. 935: Fair Accountability and Innovative Research Drug Pricing Act of 2023 - Provisions related to drug pricing S. 1067: Ensuring Timely Access to Generics Act of 2023 S. 1130: Health Care PRICE Transparency Act S. 1128: Ensuring Access to Generic Medications Act S. 1214: RARE Act - To set forth limitations on…”
$31.0M lobbying spend in 2024, all issuesQ2 2024 filing
Organizations that named S. 935 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
2 actions · newest first- Mar 22, 2023Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Mar 22, 2023Introduced in Senate